Eisai

The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called…

The Swiss drugmaker conducted two identically designed studies, each with about 1,000 participants, who were examined and queried…

Data on the drug has been promising and Biogen and Eisai are expected to file for a US approval soon with a decision expected in…

Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective 1st…

In March 2016, Dr Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer…

The companies are planning to move into the registrational stage of development for this asset as early as next year

Biogen and Eisai have jointly developed three experimental drugs for Alzheimer’s

This collaboration aims to develop a disease-modifying treatment for synucleinopathies based on network kinetics of α-synuclein…

They assured that they will work towards developing innovations to fight the COVID-19 pandemic, ensuring their timely availability…

Gilead Japan will hold marketing authorisation of Jyseleca in Japan while Eisai will be responsible for product distribution